A weekly health led newsletter grounded in evidence-based medicine along with prospective randomized controlled trials (RCTs) by medical specialists. Our goal is to help you make sense of complex scientific information and turn it into clear, evidenced based practices you can use to make better decisions about your health and wellness.

Torcetrapib did everything the theory demanded. The HDL, also termed “good cholesterol" increased 72%, and LDL termed “bad cholesterol" decreased 25%.

On paper, this past development seemed like it could be coined a gold standard for preventing heart attacks.

However, the safety monitors counted deaths shortly after. Across 15,067 patients, the Torcetrapib group had 58% more deaths compared to non intervention. Although many factors could contribute to such a finding, Pfizer stopped the trial and the drug was never sold. ILLUMINATE, 2007

Hold onto that story, because it is the reason this issue exists.

Four things are currently shown to have positive effects on a myocardial infarction risk profile: Fish Oil, Vitamin K2, Nattokinase, and Tadalafil, the drug in Cialis. All four have research behind them. Not one of them has the same exact clinical findings, which show you that they all work differently to achieve that one common goal of preventing future myocardial infarction.

THE FRAMEWORK

Every claim about a heart supplement sits on a ladder, and the rung tells you almost everything you need.

Mechanism is the bottom rung. The compound does something interesting in a dish. This is where marketing copy is derived and created.

Biomarker is next, which signifies a number in your blood moving.

Imaging is the third. A scan of your arteries have a much more favorable structure than possibly noted previously..

Then the top rung, the only one that matters to you. Did fewer people have heart attacks or die?

Torcetrapib died in that top gap. So did Niacin due to some known side effects, so it's not the first resort anymore. 

Arteriography gave some promise in reducing and even reversing plaque. Then a trial of 25,673 people found no reduction in vascular events at all, plus more diabetes and more serious infections. HPS2-THRIVE, NEJM

COMPOUND ONE

One omega-3 has climbed all four rungs. It is almost certainly not the one in your cupboard.

REDUCE-IT gave 8,179 statin-treated patients 4 grams a day of icosapent ethyl, a purified EPA. Over roughly five years, major cardiovascular events hit 17.2 percent on the drug against 22.0 percent on placebo, showing a measurable difference. REDUCE-IT, NEJM 2019

Then STRENGTH tested EPA plus DHA at the identical 4 gram dose, and it  failed outright. Same family, same dose, opposite result.

The usual explanation is a placebo argument , but the membrane biology has better support and standing.

Picture the wall of a cell as a sandwich of fat. In atherosclerosis, cholesterol inside that wall stops floating freely and clumps into hard ordered patches, like sugar crystallising out of syrup.

EPA slides into that wall, props it wider, and stops the patches forming. DHA does the reverse. It loosens the wall and encourages the very clumping EPA prevents.

That is the same family of molecules behaving in opposite directions, which is a strange and underappreciated mechanism of action.

Here is what it means for the bottle you come across. The trials that worked utilized 4 grams of a prescription-purified single molecule. Standard 1 gram fish oil was tested in 25,871 adults and missed its main target, although heart attacks specifically did fall.

High-dose omega-3 also could raise suspicion for atrial fibrillation, as noted in both large trials.

COMPOUND TWO

This one has the cleanest mechanism of the four, and the newest data.

Your body makes a protein called matrix Gla protein whose entire job is stopping calcium settling in soft tissue. It arrives switched off. Vitamin K is the key that switches it on, and without enough K2 it sits there inert while calcium builds in arterial walls.

The population data landed early and it was specific. Following 4,807 Dutch adults, the highest intake of K2 came with a coronary death rate less than half the lowest. Vitamin K1 predicted nothing at all, which is what made this worth taking seriously. Rotterdam Study, 2004

Then in June, a trial published in JAMA Cardiology gave 180 people with early coronary calcification 360 micrograms of MK-7 for two years. Their calcium mass built up about 42 percent slower than placebo. VitaK-CAC, JAMA Cardiology 2026

An earlier trial in men with severe, established valve calcification found nothing. So the honest reading is that K2 may slow calcium that has not yet set, and may not have as strong of an action to preexisting calcium in the arteries. Now the part nobody selling K2 will tell you.

Statins lower your coronary calcium score. They are the best-proven heart drug we have, they cut events sharply, and they push that number down.

They do it by draining the soft greasy core of a plaque and sealing it under a hard calcium cap. American College of Cardiology on statins and calcium scoring

COMPOUND THREE

We are starting here with a citation, because this one teaches the whole issue in a single plot.

Search nattokinase and plaque and you will find sites citing a 2017 trial in JAMA Network Open where the enzyme beat a statin on artery imaging. The study is real. It ran in the National Medical Journal of China, in Chinese, it enrolled 82 people, and it had no placebo group.

The best evidence points the other way. A three-year randomized trial gave 265 adults 2,000 fibrinolytic units daily against placebo, and artery wall thickness and stiffness progressed identically in both groups. NAPS trial, 2021

Defenders have a fair objection and it deserves a straight answer. That trial used 2,000 units. The studies reporting plaque reduction used 6,000 to 10,800, and one found that 3,600 did nothing in regards to this matter..

What Nattokinase clearly does is break down fibrin, the mesh that holds a clot together. Eight weeks of it dropped systolic blood pressure by about 5.6 mmHg in one trial, which is an outstanding advancement for just deploying nattokinase into a potential regimen.

COMPOUND FOUR

Tadalafil has become a quiet daily habit in longevity circles, and the numbers look strong. Among 8,156 men with erectile dysfunction compared against 21,012 who took nothing, Tadalafil use came with 19 percent fewer cardiovascular events and 55 percent lower cardiac death.

Penile arteries are 1 to 2 millimetres wide. Coronary arteries are 3 to 4. The same endothelial damage narrows the small vessel first, which is why erectile dysfunction usually shows up two to three years before chest symptoms and three to five years before an actual cardiac event. European Urology systematic review

THE PROTOCOL

Ask which rung it sits on, and if nobody will say, assume the bottom one (so ask yourself what is the proven mechanism of action behind said intervention).

Ask whether there was a placebo group, because a supplement tested against a drug or against no alternative cannot separate a real effect from ordinary variation.

Finally, ask yourself if the data has such effects on having lower risk of Myocardial Infarction. Although data can vary throughout time, it is important to recognize what has changed over the years versus what has remained constant.

BEFORE YOU GO

The US Preventive Services Task Force still finds the evidence insufficient to recommend for or against single-nutrient supplements for heart prevention. USPSTF recommendation

Read that as a map rather than a verdict. The lower rungs are crowded, the top one is nearly bare, and the compounds worth your attention are the ones whose trials are still climbing.

Vitamin K2 is climbing right now. We will tell you where it lands.

Educational content, not medical advice. The evidence level for each claim is spelled out so you can weigh it yourself. Talk to a clinician before starting or stopping anything.